Holen Sie sich die Stockscreener-App
2.46
7.42%
0.17
Handel nachbörslich:
2.47
0.01
+0.41%
Schlusskurs vom Vortag:
$2.29
Offen:
$2.29
24-Stunden-Volumen:
332.01K
Relative Volume:
0.98
Marktkapitalisierung:
$258.82M
Einnahmen:
$7.05M
Nettoeinkommen (Verlust:
$-30.43M
KGV:
-6.4942
EPS:
-0.3788
Netto-Cashflow:
$21.84M
1W Leistung:
+8.37%
1M Leistung:
+12.33%
6M Leistung:
+108.47%
1J Leistung:
+35.91%
1-Tages-Spanne:
$2.20
$2.49
1-Wochen-Bereich:
$2.20
$2.58
52-Wochen-Spanne:
$1.07
$4.62
Proqr Therapeutics N V Stock (PRQR) Company Profile
Firmenname
Proqr Therapeutics N V
Sektor
Branche
Telefon
-
Adresse
-
Vergleichen Sie PRQR mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PRQR
Proqr Therapeutics N V
|
2.46 | 241.24M | 7.05M | -30.43M | 21.84M | -0.3788 |
|
VRTX
Vertex Pharmaceuticals Inc
|
412.22 | 104.45B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
469.36 | 60.95B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.60 | 59.11B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
812.95 | 49.23B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.94 | 35.92B | 4.56B | -176.77M | 225.30M | -1.7177 |
Proqr Therapeutics N V Stock (PRQR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-29 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2025-04-29 | Eingeleitet | Evercore ISI | Outperform |
| 2025-03-10 | Hochstufung | Citigroup | Neutral → Buy |
| 2025-01-10 | Eingeleitet | Oppenheimer | Outperform |
| 2024-10-29 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2023-11-08 | Hochstufung | Chardan Capital Markets | Neutral → Buy |
| 2023-03-30 | Hochstufung | JMP Securities | Mkt Perform → Mkt Outperform |
| 2022-12-22 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2022-02-14 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-02-11 | Herabstufung | Raymond James | Strong Buy → Mkt Perform |
| 2022-02-11 | Herabstufung | Stifel | Buy → Hold |
| 2022-02-01 | Eingeleitet | Raymond James | Strong Buy |
| 2021-05-03 | Eingeleitet | Stifel | Buy |
| 2021-03-25 | Bestätigt | Citigroup | Buy |
| 2020-11-03 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2019-03-12 | Bestätigt | Chardan Capital Markets | Buy |
| 2018-12-19 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2018-11-15 | Eingeleitet | Citigroup | Buy |
| 2018-09-19 | Eingeleitet | Evercore ISI | Outperform |
| 2017-09-26 | Bestätigt | JMP Securities | Mkt Outperform |
| 2016-06-20 | Eingeleitet | Chardan Capital Markets | Neutral |
| 2014-10-15 | Eingeleitet | Deutsche Bank | Buy |
| 2014-10-13 | Eingeleitet | H.C. Wainwright | Buy |
Alle ansehen
Proqr Therapeutics N V Aktie (PRQR) Neueste Nachrichten
Retinitis Pigmentosa Market to Expand Significantly by 2034, States DelveInsight Report | SparingVision SAS, ProQR Therapeutics NV, Viridian Therapeutics Inc, 4D Molecular Therapeutics Inc - The Globe and Mail
How moving averages guide ProQR Therapeutics N.V. tradingQuarterly Trade Report & Technical Entry and Exit Tips - newser.com
Key metrics from ProQR Therapeutics N.V.’s quarterly dataWeekly Trend Recap & High Return Trade Opportunity Guides - newser.com
ProQR Therapeutics N.V. stock retracement – recovery analysisWatch List & Accurate Technical Buy Alerts - newser.com
Is ProQR Therapeutics N.V. stock a good choice for value investorsPortfolio Return Summary & Real-Time Buy Signal Alerts - newser.com
Risk adjusted return profile for ProQR Therapeutics N.V. analyzedJuly 2025 Update & Community Supported Trade Ideas - newser.com
Will ProQR Therapeutics N.V. stock outperform international peersRisk Management & Daily Growth Stock Tips - newser.com
ProQR Therapeutics to Participate in Upcoming Investor Conferences with Focus on RNA Editing Technology - Quiver Quantitative
ProQR to Participate in Upcoming Investor Conferences in October 2025 - GlobeNewswire
Oct 14–22, 2025: ProQR to Present at Three Investor Conferences; RNA Editing Panel Oct 21, webcasts available - Stock Titan
ProQR Therapeutics N.V. stock chart pattern explainedWeekly Profit Recap & AI Optimized Trade Strategies - newser.com
Quantitative breakdown of ProQR Therapeutics N.V. recent moveMarket Movement Recap & Fast Entry and Exit Trade Plans - newser.com
Risk vs reward if holding onto ProQR Therapeutics N.V.2025 Historical Comparison & AI Enhanced Trading Signals - newser.com
ProQR Therapeutics' (PRQR) Sell (D-) Rating Reiterated at Weiss Ratings - MarketBeat
ProQR Therapeutics N.V.'s (NASDAQ:PRQR) Price Is Out Of Tune With Revenues - simplywall.st
How ProQR Therapeutics N.V. (0PQ) stock reacts to new regulationsWeekly Trade Recap & Consistent Income Trade Recommendations - newser.com
Can you recover from losses in ProQR Therapeutics N.V.2025 Price Momentum & High Return Stock Watch Alerts - newser.com
What MACD and RSI say about ProQR Therapeutics N.V.Earnings Summary Report & Weekly High Potential Alerts - newser.com
Analyzing drawdowns of ProQR Therapeutics N.V. with statistical toolsDip Buying & Long-Term Growth Stock Strategies - newser.com
ProQR Therapeutics N.V. (NASDAQ:PRQR) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
How to escape a deep drawdown in ProQR Therapeutics N.V.Breakout Watch & Weekly Chart Analysis and Guides - newser.com
Will ProQR Therapeutics N.V. (0PQ) stock outperform energy sector in 2025Portfolio Risk Report & Fast Exit Strategy with Risk Control - newser.com
Should you wait for a breakout in ProQR Therapeutics N.V.Day Trade & Stepwise Swing Trade Plans - newser.com
Order flow analysis tools used on ProQR Therapeutics N.V.Price Action & Daily Stock Momentum Reports - newser.com
What MACD signals say about ProQR Therapeutics N.V.Market Volume Summary & Free Technical Pattern Based Buy Signals - newser.com
ProQR Therapeutics (NASDAQ:PRQR) Shares Cross Above 50-Day Moving AverageShould You Sell? - MarketBeat
What drives ProQR Therapeutics NV stock priceBearish Engulfing Patterns & Reduce Losses With Smart Exit Strategies - earlytimes.in
Tools to assess ProQR Therapeutics N.V.’s risk profile2025 Valuation Update & AI Based Buy and Sell Signals - newser.com
ProQR Therapeutics NV Stock Analysis and ForecastCurrency Fluctuation Impact & Low Risk Wealth Building - earlytimes.in
Finanzdaten der Proqr Therapeutics N V-Aktie (PRQR)
Umsatz
Nettogewinn
Free Cashflow
ENV
5.15%
1.45%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):